北京大學(xué)腫瘤醫(yī)院（北京腫瘤醫(yī)院、北京大學(xué)臨床腫瘤學(xué)院、北京市腫瘤防治研究所）始建于1976年，是我國著名的大型現(xiàn)代化三級甲等腫瘤?？漆t(yī)院，是集醫(yī)、教、研于一體，預(yù)防、治療、康復(fù)相結(jié)合的腫瘤防治研究中心。

院所是北京抗癌協(xié)會、北京癌癥康復(fù)會、介入治療專業(yè)委員會、影像專業(yè)委員會、護(hù)理專業(yè)委員會的掛靠和依托單位。醫(yī)院還設(shè)有北京市胃癌防治中心、北京市乳腺癌防治中心、北京市影像介入治療中心、超聲診斷等北京市重點學(xué)科。在腫瘤學(xué)基礎(chǔ)理論研究、我國若干種常見腫瘤的臨床診斷與治療、胃癌高發(fā)現(xiàn)場的預(yù)防干預(yù)等領(lǐng)域均有創(chuàng)新性和領(lǐng)先的工作，在國內(nèi)外頗具影響。

全院現(xiàn)有在編職工990人，其中專業(yè)技術(shù)人員占87％，高級技術(shù)職稱人員162人，博士生導(dǎo)師32人，突貢專家3名；享受政府特殊津貼者24名；國家杰出青年3名；國家百千萬人才工程人選1名；新世紀(jì)百千萬人才工程5名；北京市跨世紀(jì)優(yōu)秀人才5名；北京市科技新星人選16名。入選北京市醫(yī)學(xué)領(lǐng)軍人才1名，學(xué)科帶頭人3名。學(xué)科帶頭人及業(yè)務(wù)骨干中90％以上為留學(xué)（研修）歸國人員。

醫(yī)院于1997年通過三級甲等醫(yī)院評審?，F(xiàn)有病床700張，26個臨床科室，26個病區(qū)，13個醫(yī)技科室。年住院人數(shù)2.3萬余人次，年門診量28萬余人次。患者來自全國各省、市、自治區(qū)、港澳臺以及東南亞等地區(qū)。我院致力于乳腺癌、胃癌、肺癌、結(jié)直腸癌、肝癌、食管癌、惡性淋巴瘤、婦科腫瘤、頭頸部腫瘤、骨腫瘤以及惡性黑色素瘤等各種腫瘤的診斷和綜合治療。倡導(dǎo)多學(xué)科協(xié)作，整合各科室醫(yī)療資源，成立了乳腺癌、淋巴瘤、肝癌和胃癌等單病種協(xié)作組，為患者提供規(guī)范的個體化綜合治療。

我院（所）于2007年底被教育部批準(zhǔn)為“惡性腫瘤發(fā)病機(jī)制及轉(zhuǎn)化研究”重點實驗室，設(shè)有6個研究室，1個中心實驗室，1個臨床實驗室。北京市高科技實驗室—北京腫瘤分子生物學(xué)實驗室亦設(shè)在所內(nèi)。建所以來，圍繞我國常見惡性腫瘤特別是胃癌、乳腺癌癌變機(jī)理的研究、腫瘤預(yù)防與控制研究、腫瘤易感性和惡性生物學(xué)行為的研究及腫瘤生物治療研究等主要科研方向，開展了大量基礎(chǔ)和應(yīng)用研究工作，主持和承擔(dān)了“國家科技攻關(guān)”、“863”、“973”“國家自然科學(xué)基金”等項目及北京市和其它部委的重點科研項目，已獲市部級以上科研成果104項，發(fā)表論文2600多篇。其中在腫瘤學(xué)基礎(chǔ)理論研究、常見主要腫瘤的臨床診斷與治療，胃癌高發(fā)現(xiàn)場的預(yù)防干預(yù)等領(lǐng)域均有創(chuàng)新性，在國內(nèi)外具有一定影響。

我院為國家臨床藥理基地會員單位， 2000年至2007年已完成臨床試驗研究項目76項，其中國內(nèi)藥物臨床試驗52項，國際多中心臨床研究10項，醫(yī)療器械臨床試驗14項；正在進(jìn)行國內(nèi)藥物臨床試驗35項，國際多中心臨床研究11項，醫(yī)療器械臨床試驗4項。

我院是國家腫瘤學(xué)重點學(xué)科、全國腫瘤學(xué)科博士學(xué)位授權(quán)點和博士后流動站所在單位。醫(yī)學(xué)教育涵蓋本科生、碩士生、博士生、博士后和進(jìn)修生教育。每年定期舉辦全國臨床腫瘤醫(yī)師進(jìn)修班和國家繼續(xù)教育項目全國性學(xué)習(xí)班。

院所作為全國著名腫瘤中心之一，在國內(nèi)外具有日益廣泛的影響，與許多國際知名腫瘤研究機(jī)構(gòu)建立了密切的合作關(guān)系，每年不斷有國內(nèi)外專家學(xué)者來院參觀、考察、講學(xué)進(jìn)行科研協(xié)作與學(xué)術(shù)交流。院所也不斷有科研與醫(yī)技專業(yè)人員出國訪問、進(jìn)修、短期工作或參加國際學(xué)術(shù)會議。

北京腫瘤醫(yī)院愿以優(yōu)秀的腫瘤學(xué)專業(yè)人才、先進(jìn)的醫(yī)療設(shè)備、精湛的醫(yī)療技術(shù)、科學(xué)的醫(yī)院管理、舒適的就醫(yī)環(huán)境和人性化的關(guān)懷和照顧，為來自四面八方的患者提供優(yōu)質(zhì)服務(wù)。醫(yī)院的宗旨是：全方位體現(xiàn)人文精神，為腫瘤患者提供優(yōu)質(zhì)服務(wù)，讓每一位腫瘤患者在就醫(yī)中獲益。讓北京腫瘤醫(yī)院成為“院有品牌、科有特色、人有專長”、“患者滿意、員工高興、政府放心”的人民滿意醫(yī)院。

               Beijing Cancer Hospital

Medical Service:

Beijing Cancer Hospital is one of the famous large special hospitals in the field of cancer research and treatment. There are 660 hospital beds, which will be extended to 790 in 2008. A total of 26 clinical departments and 13 medical technological departments. The yearly outpatient visits are about 230,000 person-times, while the yearly hospital in-patients are about 28,000 person-times.
For the past many years, our hospital has been engaged in the diagnosis and treatment of various tumors, such as breast cancer, gastric cancer, lung cancer, colorectal cancer, liver cancer, esophageal carcinoma, malignant lymphoma, gynecological cancer, tumor of head and neck , bone tumor and melanoma. The hospital advocates the cooperation of multiple disciplines, integrate medical sources of all departments, and has established different cooperation groups for mono-disease including breast cancer, gastric cancer, lymphoma, and liver cancer, providing normalized and individualized combined treatment for the patients.

The hospital is a member of the national base for clinical pharmacology. From 2000 to 2007, the pharmacological institution of Beijing Cancer Hospital has completed 76 clinical trials, of which 52 belonged to domestic clinical trials, 10 belonged to international multi-center clinical trials, and 14 belonged to clinical trials for medical equipment. There are 50 on-going programs, of which 35 are domestic clinical trials, 11 are international multi-center clinical trials, and 4 are clinical trials for medical equipment. Now the

hospital is performing 24 programs, including international clinical trials and domestic clinical trials for new drugs.
The breast cancer patients treated with conservative surgery in the Breast Cancer Center of the hospital have reached 51%. The Department of Gastrointestinal Surgery has developed multimodality therapy for gastric cancer and neo-adjunctive radiochemical therapy for rectal cancer. The Department of Hepatic, Biliary & Pancreatic Surgery has performed various kinds of hepatic and pancreatic operations with high difficulty, and advocated the multimodality therapy for liver metastasis of colon carcinoma. The Department of Thoracic Surgery has developed bisaxillary lymphnode dissection for carcinoma of gastric cardia, high level cervical excision of esophageal carcinoma, complex surgery of lung cancer such as plasty of pulmonary artery, and chest minimally invasive surgery. The Department of Respiratery Oncology has established the normalized chemotherapy regimens for lung cancer of advanced stage, making that the median survival and yearly survival rate of NSCLC and SCLC reach or approach the international level, respectively. The Department of Dastrointestinal Oncology has been engaged in promoting the normalized chemotherapy for gastric cancer and colorectal cancer. The Department of lymphoma & Hematologic Oncology has been walking in the front row in China in the field of diagnosis and treatment of malignant lymphoma. The Department of Renal Cancer & Melanoma has treated patients with renal cancer and melanoma by bio-immunotherapy. The Department of Radiotherapy has treated malignant tumors by dynamic intensity modulated radiation therapy (DIMRT), concomitant chemo-radiotherapy, clinical application of radiosensitizer, and gene therapy combined with radiotherapy and hyperthermia therapy. The Department of Integrated Traditional Chinese and Western Medicine has alleviated the pain of patients maximally under the premise of effective control of tumor, and established the agreement prescriptions to relieve side effects of chemotherapy. The PACS/RIS system in the Department of Medical Imaging has developed studies on diagnosis, staging, evaluation and prediction of efficacy by combination of various kinds of imaging methods. The Department of Ultrasound has developed ultrasound-guided radiofrequency ablation to treat liver cancer, increasing the diagnosis rate and differential diagnosis rate. The hospice is one of the service agencies for cancer patients established in 20 key hospitals national wide by “The Li Ka Shing Foundation National Hospice Service Programme”, which provides free drop-in medical services and analgesic drugs for patients with advanced cancer to improve their quality of life.

Medical Teaching

Peking University School of Oncology is a national key subject on oncology, with a teacher team of reasonable knowledge and age structure. There are 45 professors, 71 associated professors, 112 with doctoral degree, and 101 with master’s degree. The school has 7 specialized teaching and researching divisions. There are 21 doctoral supervisors and 28 master supervisors. Furthermore, the school has invited several top experts from America, French and Japan to hold the post of visiting professor in related subjects perennially.
Peking University School of Oncology has established a medical teaching system with multi-strata and multi-orbit, including postgraduate education, education after graduation and continuing medical education. The school is the awarding station for doctoral degree and postdoctoral station of oncology. It assumes the responsibility in cultivation of postgraduates from 6 majors, including oncology, biochemistry and molecular biology, cellular biology, imaging medicine and nuclear medicine, epidemiology and health statistics, integrated traditional Chinese and western medicine, and the graduate stage of 8-year bachelor-master-doctor continuous study. Since 1988, the school has cultivated 394 post-graduate, including 151 with doctoral degree and 243 with master’s degree. There are 14 out-station post-doctoral researchers, and 6 post doctoral researchers at present. In addition, the school enrolls students and post-graduates coming from abroad each year.

The school and hospital have been developing international and domestic communication and cooperation actively. It has established long-term cooperation with many famous domestic and international medical schools, including Duke University in the USA and Louis Pasteur University in France, and famous research institutes, such as NCI, MD. ANDERSON, and MSKCC in USA. It also has send out several scholars in related subjects each year to participate in academic communication. Many doctors have been sent abroad each year for advanced study with the foundation of “Climbing Plan” established by the school. The school is responsible for more than 10 national-level or city-level continuing medical education programs and hold academic visit, advanced study, and academic communication of averagely 800 person-times per year.

Scientific research

The institute was founded in 1976, including 7 laboratories for basic research composed of more than 80 scientists and technicians with high quality, a ministerial key laboratory, and a field study base for high incidence of gastric cancer that with a history of 30 years.
Since its foundation, the school (institute) has been performed and responsible for 34 national key projets, 79 national programs with special funds, and 10 international cooperative programs. In addition, the institute has been cooperated with NCI of America since 1985. It has received about RMB 1,000,0000 yuan yearly as fund for scientific research in the recent five years. During 30 years from the foundation of the institute, It has received 5 national-level achievement awards, 102 ministerial or provincial-level awards, and 14 patents. The scientists and doctors of the institute have published more than 2500 papers in foreign and domestic journals specialized in

biomedicine, including 280 SCI papers, and 22 papers with influence factor(IF) higher than 5 since 2001.
The school (institute) focuses on three research directions, including prevention of cancer, molecular mechanisms of the carcinogenesis and development of tumor, and increasing the efficacy of individualized combined treatment of common tumors. It has obtained a series of progress, such as, “Multiple factor randomized chemical intervention study on gastric cancer” directed by prof. You Weicheng, which is a double-blind, randomized, and controlled intervention study on gastric cancer and precancerous changes with the biggest sample size in world and a duration as long as 7.5 years. It is shown that by the strict population control study, clearance of helicobacterpylori (Hp) can significantly decrease the incidence of precancerous changes and gastric cancer, which is of great directive significance to the prevention of gastric cancer (JNCI, IF=15.171). The study of “improving the efficacy of ultrasonic guided radiofrequency ablation on liver cancer” directed by prof. Chen Minhua has increased the efficacy of radiofrequency ablation on large liver cancer and multiple liver cancer and improved survival time and quality of life by establishing mathematic model and combining of other subjects for the first time internationally (The study has been widely approved by domestic and foreign peers, and has been invited to report for 4 times on international meetings). The breast-conserving rate of treatment for breast cancer further increased from 24% in 2001 to 51% in 2006 (the domestic level is 5%). The preoperation neoadjuvant chemotherapy and individualized normalized treatment for gastric cancer has increased the resectable rate of gastric cancer with mediate and advanced stage. Now available two-year survival rate has been increased from 60% to 75%. The practice of normalized total mesorectal excision has decreased partial recurrence rate of rectal cancer from 12% to 6%. Preoperation radiotherapy has decreased the pathological staging of rectal cancer, and increased the anus-conserving rate from 50% to more than 70%. The treatment level of other tumors (such as lung cancer, malignant lymphoma, renal carcinoma, and melanoma) is also in the front row in China. Furthermore, it has performed in-depth studies on molecular pathology, gene polymorphism, gene array, and gene phenotype of tumors, and combined basic and clinical study on tumor antibody.